Jazz Pharmaceuticals Announces CEO Succession Plan as Co-Founder Bruce Cozadd Prepares to Retire

Retirement Announcement:
Bruce Cozadd, co-founder, chairperson, and CEO of Jazz Pharmaceuticals, has announced his intention to retire from his role as CEO upon the appointment of a successor, expected by the end of 202524.

Succession Plan:
The Board of Directors will lead a comprehensive internal and external search for a new CEO, aiming to complete the process in 202524.

Continued Leadership:
Cozadd will continue serving as Chairperson of the Board of Directors, providing ongoing leadership and strategic guidance to the company2.

Company Performance:
Jazz Pharmaceuticals remains on track to meet its full-year 2024 total revenue guidance of between $4.0 billion and $4.1 billion2.

Legacy:
Cozadd has been instrumental in transforming Jazz into a diversified global biopharmaceutical company with a robust portfolio in neuroscience and oncology over his nearly 22-year tenure23.

Growth Strategy:
The company has developed into a market leader with a patient-centric approach to R&D and a commitment to providing life-changing treatments for patients with unmet medical needs2.

Sources:

2. https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-ceo-succession-plan-302332980.html

3. https://endpts.com/jazz-pharmaceuticals-ceo-and-co-founder-announces-retirement/

4. https://www.fiercepharma.com/pharma/cozadds-coda-jazz-unveils-succession-plan-longtime-ceo-and-co-founder-plots-retirement